

Simona Corso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4822451/publications.pdf>

Version: 2024-02-01

46
papers

4,432
citations

159585

30
h-index

233421

45
g-index

47
all docs

47
docs citations

47
times ranked

6680
citing authors

#	ARTICLE	IF	CITATIONS
1	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Cancer Discovery</i> , 2013, 3, 658-673.	9.4	585
2	The Semaphorin 4D receptor controls invasive growth by coupling with Met. <i>Nature Cell Biology</i> , 2002, 4, 720-724.	10.3	391
3	Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. <i>Journal of Experimental Medicine</i> , 2008, 205, 1673-1685.	8.5	233
4	Sema4D induces angiogenesis through Met recruitment by Plexin B1. <i>Blood</i> , 2005, 105, 4321-4329.	1.4	226
5	Cancer therapy: can the challenge be MET?. <i>Trends in Molecular Medicine</i> , 2005, 11, 284-292.	6.7	218
6	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. <i>Cell Metabolism</i> , 2018, 28, 848-865.e6.	16.2	184
7	MicroRNAs Impair MET-Mediated Invasive Growth. <i>Cancer Research</i> , 2008, 68, 10128-10136.	0.9	168
8	Interplay between scatter factor receptors and B plexins controls invasive growth. <i>Oncogene</i> , 2004, 23, 5131-5137.	5.9	164
9	<i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2010, 70, 7580-7590.	0.9	164
10	Hepatocyte growth factor and its receptor are required for malaria infection. <i>Nature Medicine</i> , 2003, 9, 1363-1369.	30.7	133
11	Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. <i>Oncogene</i> , 2007, 26, 6968-6978.	5.9	131
12	Silencing the MET oncogene leads to regression of experimental tumors and metastases. <i>Oncogene</i> , 2008, 27, 684-693.	5.9	126
13	Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). <i>Oncogene</i> , 2006, 25, 3689-3698.	5.9	125
14	MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. <i>Cancer Research</i> , 2006, 66, 4750-4757.	0.9	123
15	Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. <i>Blood</i> , 2011, 117, 419-428.	1.4	114
16	HGF/MET signalling protects Plasmodium-infected host cells from apoptosis. <i>Cellular Microbiology</i> , 2005, 7, 603-609.	2.1	100
17	Targeted therapies for gastric cancer: failures and hopes from clinical trials. <i>Oncotarget</i> , 2017, 8, 57654-57669.	1.8	99
18	Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. <i>Molecular Cancer</i> , 2010, 9, 121.	19.2	95

#	ARTICLE	IF	CITATIONS
19	Semaphorin 4D regulates gonadotropin hormone-releasing hormone-1 neuronal migration through PlexinB1-Met complex. <i>Journal of Cell Biology</i> , 2008, 183, 555-566.	5.2	92
20	p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. <i>Journal of Cell Science</i> , 2005, 118, 4689-4700.	2.0	90
21	Microsatellite instability in Gastric Cancer: Between lights and shadows. <i>Cancer Treatment Reviews</i> , 2021, 95, 102175.	7.7	88
22	Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. <i>Science Signaling</i> , 2009, 2, ra80.	3.6	84
23	Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective. <i>Cancer Discovery</i> , 2013, 3, 978-992.	9.4	84
24	YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. <i>Neoplasia</i> , 2017, 19, 1012-1021.	5.3	77
25	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	7.0	76
26	Activation of RAS family members confers resistance to ROS1 targeting drugs. <i>Oncotarget</i> , 2015, 6, 5182-5194.	1.8	72
27	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , 2019, 79, 5884-5896.	0.9	53
28	How Can Gastric Cancer Molecular Profiling Guide Future Therapies?. <i>Trends in Molecular Medicine</i> , 2016, 22, 534-544.	6.7	50
29	The Tetraspanin CD151 Is Required for Met-dependent Signaling and Tumor Cell Growth. <i>Journal of Biological Chemistry</i> , 2010, 285, 38756-38764.	3.4	46
30	EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1327-1335.	2.5	43
31	Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. <i>Oncogene</i> , 2017, 36, 1200-1210.	5.9	28
32	A Correction to the Research Article Titled: "Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction" by A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino. <i>Science Signaling</i> , 2009, 2, er11.	3.6	23
33	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	3.3	22
34	ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. <i>British Journal of Cancer</i> , 2003, 88, 396-400.	6.4	19
35	Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts. <i>Neoplasia</i> , 2018, 20, 443-455.	5.3	17
36	Increase of <i>MET</i> gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. <i>Molecular Oncology</i> , 2014, 8, 1561-1574.	4.6	15

#	ARTICLE	IF	CITATIONS
37	Patient-Derived Orthotopic Xenograft models in gastric cancer: a systematic review. Updates in Surgery, 2020, 72, 951-966.	2.0	14
38	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 3126-3140.	7.0	11
39	Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells. Cancers, 2020, 12, 2218.	3.7	10
40	Molecularly Targeted Therapies for Gastric Cancer. State of the Art. Cancers, 2021, 13, 4094.	3.7	10
41	Patient-Derived Cancer Models. Cancers, 2020, 12, 3779.	3.7	9
42	Targeted therapies in cancer and mechanisms of resistance. Journal of Molecular Medicine, 2014, 92, 677-679.	3.9	6
43	Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer, 2021, 24, 897-912.	5.3	6
44	hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of <i>MET</i> -addicted cancers. Journal of Experimental and Clinical Cancer Research, 2022, 41, 112.	8.6	5
45	A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer. Translational Oncology, 2022, 15, 101260.	3.7	3
46	Mechanisms of Resistance to Molecular Therapies Targeting the HGF/MET Axis. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 67-87.	0.1	0